Hope for rare disease: new drug trial for VEXAS syndrome begins
NCT ID NCT07569081
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called momelotinib in 136 adults with VEXAS syndrome, a rare inflammatory disease caused by a genetic mutation. The goal is to see if the drug can reduce disease activity, with participants receiving either momelotinib or a placebo. This is a phase 2/3 trial, meaning it checks both the right dose and how well the drug works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VEXAS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug tame VEXAS syndrome and cut steroid dependence?
- Hidden genetic syndrome may explain mysterious inflammation in older adults
- Experimental drug pacritinib takes aim at rare inflammatory VEXAS syndrome
- Massive study to uncover hidden link between blood mutations and immune disorders
- New study uses DNA tests to catch blood cancers before they start
- Could a stem cell transplant tame VEXAS syndrome?